Web Exclusives

Considerations in first-line and second-line therapy selection in non–small-cell lung cancer without genetic alterations were presented in a recent review article. Read More ›

Although generally mild adverse events are associated with the use of immune checkpoint inhibitors for non–small-cell lung cancer, occasionally serious complications may result. Read More ›

A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs. Read More ›

Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors. Read More ›

A retrospective cohort study demonstrates patients with inoperable non–small-cell lung cancer receiving aspirin have improved overall survival compared with patients not receiving aspirin. Read More ›

A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect. Read More ›

Treatment with ribociclib and an aromatase inhibitor or fulvestrant for hormone receptor–positive, HER2-negative metastatic breast cancer did not increase the risk of thrombosis in the real-world setting. Read More ›

Palbociclib combined with letrozole is associated with improved outcomes for patients with hormone receptor–positive, HER2-negative metastatic breast cancer with lung or liver metastases in the first-line setting Read More ›

Study results reinforce that patient selection for abemaciclib treatment is critical to ensure adequate efficacy and safety. Read More ›

Recently released results using liquid biopsy shows KRAS G12C mutation in patients with NSCLC can be lost or acquired at progressive disease. Read More ›